SHOULD CATASTROPHIC RISKS BE INCLUDED IN A REGULATED COMPETITIVE HEALTH-INSURANCE MARKET

被引:28
作者
VANDEVEN, WPMM
SCHUT, FT
机构
[1] Institute of Health Care Policy and Management, Erasmus University, 3000 DR Rotterdam
关键词
CATASTROPHIC RISK; REGULATED COMPETITION; HEALTH INSURANCE; QUALITY SKIMPING; HEALTH CARE REFORM;
D O I
10.1016/0277-9536(94)90240-2
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
In 1988 the Dutch government launched a proposal for a national health insurance based on regulated competition. The mandatory benefits package should be offered by competing insurers and should cover both non-catastrophic risks (like hospital care, physician services and drugs) and catastrophic risks (like several forms of expensive long-term care). However, there are two arguments to exclude some of the catastrophic risks from the competitive insurance market, at least during the implementation process of the reforms. Firstly, the prospects of a workable system of risk-adjusted payments to the insurers that should take away the incentives for cream skimming are, at least during the next 5 years, more favorable for the non-catastrophic risks than for the catastrophic risks. Secondly, even if a workable system of risk-adjusted payments can be developed, the problem of quality skimping may be relevant for some of the catastrophic risks, but not for non-catastrophic risks. By 'quality skimping' we mean the reduction of the quality of care to a level which is below the minimum level that is acceptable to society. After 5 years of health care reforms in the Netherlands new insights have resulted in a growing support to confine the implementation of the reforms to the non-catastrophic risks. In drawing (and redrawing) the exact boundaries between different regulatory regimes for catastrophic and non-catastrophic risks, the expected benefits of a cost-effective substitution of care have to be weighted against the potential harm caused by cream skimming and quality skimping.
引用
收藏
页码:1459 / 1472
页数:14
相关论文
共 11 条
[1]   APPLYING COST-EFFECTIVENESS ANALYSIS - THE INSIDE STORY [J].
EDDY, DM .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1992, 268 (18) :2575-2582
[2]   POLITICAL DECISION-MAKING IN HEALTH-CARE - THE DUTCH CASE [J].
ELSINGA, E .
HEALTH POLICY, 1989, 11 (03) :243-255
[4]   ON THE IDEAL MARKET-STRUCTURE FOR 3RD-PARTY PURCHASING OF HEALTH-CARE [J].
ENTHOVEN, AC .
SOCIAL SCIENCE & MEDICINE, 1994, 39 (10) :1413-1424
[5]  
ENTHOVEN AC, 1987, P C REGULATED COMPET
[6]   THE UK HEALTH REFORMS - THE FUNDHOLDING EXPERIMENT [J].
GLENNERSTER, H ;
MATSAGANIS, M .
HEALTH POLICY, 1993, 23 (03) :179-191
[7]  
*MIN WELF HLTH CUL, 1990, WERK ZORGV, P21545
[8]  
*MIN WELF HLTH CUL, 1988, VER VERZ, P27
[9]   WORKABLE COMPETITION IN HEALTH-CARE - PROSPECTS FOR THE DUTCH DESIGN [J].
SCHUT, FT .
SOCIAL SCIENCE & MEDICINE, 1992, 35 (12) :1445-1455
[10]  
VANDEVEN WPM, 1992, HLTH EC WORLDWIDE, P23